Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06469216
Other study ID # 05-2023-018
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date April 1, 2024
Est. completion date October 2025

Study information

Verified date June 2024
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized placebo-controlled clinical trial to evaluate efficacy of hyaluronic acid in prevention of acute radiation proctitis among oncology patient population especially who are diagnosed with abdomeno-pelvic tumors and subsequently required radiotherapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 42
Est. completion date October 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - All patients diagnosed with pelvic or gastrointestinal malignancies (tumors in uterus, cervix, prostate, seminal vesicles, kidney, colon, etc.), - All patients who required adjuvant or radical radiation therapy; - Age < 80 years; - Karnofsky Performance Status = 60 Exclusion Criteria: - Patients were excluded if they had - gt; previous pelvic radiotherapy, - gt; inflammatory bowel disease or - gt; rectal issues (e.g., haemorrhoids). - Patients diagnosed with cancer rectum

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Hyaluronic Acid
Hyaluronic Acid to be used as sodium hyaluronate powder plus inactive ingredient (Carboxy methyl cellulose) and to be dissolved in distilled water
Other:
Placebo
Inactive ingredient (Carboxy methyl cellulose) to be used as powder and to be dissolved in distilled water

Locations

Country Name City State
Egypt Ahmed Maher teaching hospitals Cairo
Egypt Al-Ahrar teaching hospital Zagazig Sharqia

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time (in days) to occurrence of Acute Radiation Proctitis for each patient: time from the first day of radiation therapy for up to 3 months
See also
  Status Clinical Trial Phase
Completed NCT00828399 - Prevention of Acute Radiation Enteritis With Glutamine Phase 4